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Abstract
Influenza viruses are global pathogens that infect approximately 10–20% of the world’s
population each year. Vaccines, including the live attenuated influenza vaccine (LAIV), are the
best defense against influenza infections. The LAIV is a novel vaccine that actively replicates in
the human nasal epithelium and elicits both mucosal and systemic protective immune responses.
The differences in replication and innate immune responses following infection of human nasal
epithelium with influenza seasonal wild type (WT) and LAIV viruses remain unknown. Using a
model of primary differentiated human nasal epithelial cell (hNECs) cultures, we compared
influenza WT and antigenically-matched cold adapted (CA) LAIV virus replication and the
subsequent innate immune response including host cellular pattern recognition protein expression,
host innate immune gene expression, secreted pro-inflammatory cytokine production, and
intracellular viral RNA levels. Growth curves comparing virus replication between WT and LAIV
strains revealed significantly less infectious virus production during LAIV compared with WT
infection. Despite this disparity in infectious virus production the LAIV strains elicited a more
robust innate immune response with increased expression of RIG-I, TLR-3, IFNβ, STAT-1, IRF-7,
MxA, and IP-10. There were no differences in cytotoxicity between hNEC cultures infected with
WT and LAIV strains as measured by basolateral levels of LDH. Elevated levels of intracellular
viral RNA during LAIV as compared with WT virus infection of hNEC cultures at 33°C may
explain the augmented innate immune response via the up-regulation of pattern recognition
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receptors and down-stream type I IFN expression. Taken together our results suggest that the
decreased replication of LAIV strains in human nasal epithelial cells is associated with a robust
innate immune response that differs from infection with seasonal influenza viruses, limits LAIV
shedding and plays a role in the silent clinical phenotype seen in human LAIV inoculation.
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INTRODUCTION
Influenza viruses are global pathogens that infect approximately 10–20% of the world’s
population each year contributing to an excess in morbidity and mortality (1). Annual
immunization, including the Live Attenuated Influenza Vaccine (LAIV) and the trivalent
inactivated influenza vaccine (TIV), remain the world’s best defense against seasonal
influenza.
LAIV strains are nasal vaccines that actively replicate in the human nasal epithelium and
elicit a protective mucosal immune response without causing clinical disease. The initial
LAIV was originally developed by cold passage of a strain of influenza (H2N2; A/Ann
Arbor/6/60) in a primary chicken kidney cell line. The virus isolated from these conditions
exhibited three novel phenotypes including the ability to replicate at cooler temperatures
(cold adapted; CA), restricted replication at temperatures above 39°C (temperature sensitive;
TS), and lack of clinical disease in animal models and human experiments (attenuation; att)
(2, 3). Previous studies, comparing cold adapted LAIV strains and antigenically matched
influenza viruses, in non-human and immortalized cell lines have identified mutations in the
PB1, PB2, M, PA, and NP segments of the LAIV which have been associated with each of
these phenotypes. While specific mutations have been associated with decreased replication
or attenuation in animal models the actual mechanisms, including how the live attenuated
influenza vaccine is able to elicit a protective immune response despite lower replication at
the true site of infection – the human nasal epithelium remain unknown.
Human nasal epithelial cells are of particular importance in influenza virus and vaccine
infection as they are not only the principle cells infected but are also key cells responsible
for initiating an effective yet controlled immune response (4, 5). Influenza virus infection of
nasal epithelial cells induces an innate antiviral response in addition to the recruitment of
adaptive immune cells. An initial epithelial cell-specific innate immune response is elicited
through the interaction of host cell pattern recognition receptors (PRRs; including TLR3,
TLR7, and RIG-I) and viral RNA. The recognition of viral RNA by PRRs result in the
production of Type I IFN that lead to induction of down stream signaling molecules such as
STAT-I as well as antiviral interferon stimulated genes including myxovirus resistance gene
A (MxA) (5). Together these innate immune mediators act to limit virus replication.
Additionally, engagement of PRRs by influenza viral RNA also trigger the production and
release of the neutrophil chemokine IL-8 and IP-10 which recruit Th1 activated T cells, NK
cells, and dendritic cells into the airway (6). It is clear that the innate immune response
directed by the nasal epithelium following influenza virus or vaccine infection plays a key
role in limiting early virus replication and orchestrating an effective adaptive immune
response.
In this study we characterize the differences in virus replication and the innate immune
response to infection with a WT seasonal influenza virus and an antigenically-matched cold
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adapted (CA) LAIV strain in the principal cells infected by influenza viruses, human nasal
epithelial cells, in order to begin to understand how LAIV viruses are able to replicate in the
human nasal epithelium yet not cause clinical disease.
MATERIAL AND METHODS
Human Nasal Epithelial Cell Procurement and Culture
Primary differentiated human nasal epithelial cells (hNECs) were obtained and cultured as
previously described (7–11). Briefly, nasal epithelial cells were obtained by gently stroking
the inferior superficial surface of the inferior turbinate several times with a Rhino-Probe
curette (Arlington Scientific, Arlington TX), which was inserted through a nasoscope.
hNECs were obtained from healthy, non-smoking, volunteers (n=7) aged 18–55 years who
identified themselves as healthy without a diagnosis of asthma or smoking related disorder.
This protocol was approved by the Institutional Review Board for Biomedical Research of
the University of North Carolina at Chapel Hill School of Medicine (IRB# 09-0716).
Primary hNECs were expanded to passage 2 in bronchial epithelial growth medium (Lonza,
Walkersville, MD), plated on collagen-coated filter supports with a 0.4um pore size
(Corning, Tewksbury, MA). Upon confluence, air-liquid-interface (ALI) conditions were
created to promote differentiation. Muco-ciliary differentiation was achieved 21–28 days
after ALI.
Viruses
Wild-type viruses were propagated on MDCK cells in Dulbecco’s Modified Eagle Medium
(DMEM, Sigma, St. Louis, MO) containing 4ug/ml N-acetyltrypsin (Sigma), 100U/ml of
penicillin, 100ug/ml of streptomycin, and 0.3% bovine serum albumin (BSA; Sigma). The
viruses used in this study included a seasonal Wild Type (WT) virus, A/California/10/78
(H1N1), and an antigenically matched cold-adapted (CA) LAIV strain, A/California/10/78
CR37 CL1, which were kindly provided by K. Subbarao at the NIAID/NIH.
Virus Infections
High-multiplicity of infection (MOI) growth curves were generated by infecting hNEC
cultures in 12-well plates at an estimated MOI of 10 TCID50/ml per cell. Inoculums were
calculated based on known concentration of stock viruses to achieve an estimated MOI of 10
and then confirmed by back-titer in parallel with apical samples at designated time points.
Inoculums and stock virus were also tittered by hemagglutination assay (data not shown).
Viruses were diluted in DMEM (Sigma) containing penicillin, streptomycin, and 0.3% BSA
on the apical surface for 1 hour at room temperature. The inoculum was then aspirated and
the apical and basolateral chambers were washed twice with PBS. Basolateral media
composed of equal proportions BEGM (Lonza) and DMEM (Gibco, Grand Island, NY) was
added and the cultures were incubated at 33°C. Viral infections of hNEC cultures were
performed at 33°C to faithfully represent the temperature of the human nasal epithelium (12,
13). At the indicated times, basolateral supernatants (for cytokine detection) were collected,
apical chambers were washed with 200ul of DMEM containing penicillin, streptomycin, and
0.3% BSA (apical supernatant), and both were stored at −80°C until analysis.
Virus Titers
Infectious virus titers, at the indicated time points, were measured using a TCID50/ml assay
as previously described using Madin Darby Canine Kidney Cells (MDCK) at 33°C (14).
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Bi-directional hNEC secretion of cytokines was measured by sampling apical and
basolateral chambers separately. Apical and basolateral supernatants were analyzed for IL-8
and IP-10 using commercially available ELISA kits (BD OptEIA, Biosciences, San Diego,
CA). Lower limits of detection were as follows: IL-8 = 3.1 pg/ml and IP-10 = 7.8 pg/ml.
Cytokines were assessed at 24 hours post infection in order to ensure that the innate immune
response being measured was that to virus replication rather than inoculum.
Real-time Quantitative RT-PCR
Total RNA was isolated from hNEC cultures using TRizol (Invitrogen, Grand Island, NY)
according to manufacturer’s instructions. cDNA synthesis and real-time quantitative PCR
(qPCR) were performed as previously described (15–17). Differences in gene expression
results were determined with the ΔΔCt method and normalized first to β-actin then to mock-
infected cultures and presented as fold change in gene expression. Cell associated influenza
viral mRNA was determined by qRT-PCR using primers specific for the influenza A virus
M segment in paired samples. Differences in influenza A virus M segment detected were
determined with the ΔΔCt method and normalized to a WT sample, since no RNA was
detected in mock-infected samples.
Statistical Analysis
Experiments conducted in hNEC cultures from 7 healthy donors were paired for analysis.
Replication kinetics for wild-type seasonal viruses and antigenically-matched cold-adapted
vaccine strains were compared using two-way analysis of variance (ANOVA) with repeated
measures. Virus titers, fold change of innate immune gene and fold change of chemokine
expression at 24 hours post infection were compared using non-parametric, paired t tests
(Wilcoxon signed rank test). All statistical analyses were done using Prism, version 5.0
(GraphPad Software Inc.). *p<.05; ***p<.001.
RESULTS
Live Attenuated Influenza Vaccine (LAIV) strains exhibit marked restriction in replication
during infection of human Nasal Epithelial (hNECs) Cultures
Live Attenuated Influenza Vaccine strains are cold-adapted viruses that elicit a protective
mucosal immune response without causing clinical disease in contrast to wild-type (WT)
seasonal viruses that result in varying phenotypes of upper and lower respiratory tract
disease. In order to better understand how infection of human nasal epithelial cells with
LAIV strains differ from infection with WT viruses at the true site of infection – the human
nasal epithelium, we utilized hNEC cultures obtained from healthy non-smoking volunteers
to compare both virus replication and the epithelial cell innate immune response to infection.
At 33°C, LAIV viruses exhibited significantly reduced replication in hNEC cultures (Figure
1) with the WT viruses producing approximately 165 fold more infectious virus than the
antigenically-matched LAIV strain at 24 hours post infection (HPI).
Despite a decrease in infectious virus production, LAIV infection of hNEC cultures elicits
an enhanced innate immune response
To compare the innate immune response during infection of human nasal epithelial cell
cultures with LAIV and WT influenza viruses at 33°C we used quantitative RT-PCR to
measure the expression of pattern recognition receptors (PRRs) including RIG-I and TLR-3.
At 24 hours post infection, there was significantly greater expression of RIG-I and TLR-3 in
LAIV, as compared with WT infected hNEC cultures (Figure 2 A and B). To confirm and
expand these results we compared the down-stream expression of PRR signaling including
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Interferon-β (IFN-β) and interferon regulatory factor 7 (IRF-7). Consistent with increased
PRR signaling, there was significantly greater levels of IFN-β and IRF-7 in LAIV-infected
compared with WT-infected hNEC cultures (Figure 3 A and B). Similarly, IFN-stimulated
genes including MxA and STAT-I were also expressed at significantly higher levels in
LAIV-infected cultures (Figure 3 C and D). Collectively, these data reveal that there is a
greater innate immune gene expression in LAIV infected hNEC cultures, as compared with
WT infection, despite significantly restricted vaccine replication.
LAIV infection of hNEC cultures results is significantly greater levels of cell-associated
viral RNA
To explore the etiology of the increased innate immune gene expression during LAIV
infection of hNEC cultures we compared the level of viral RNA inside infected hNECs.
Using primers specific for the M segment, viral RNA was amplified from total RNA and
compared using the ΔΔCT method as previously described (15). At 24 hours post infection,
there was significantly greater levels of viral RNA in LAIV- as compared with WT infected
hNEC cultures despite a 165 fold higher level of infectious virus production in the latter
(Figure 4). Together these data demonstrate that although inoculation with LAIV results in
decreased replication in hNEC cultures it elicits a greater epithelial cell-specific innate
immune response, likely due to increased levels of viral RNA within infected nasal
epithelial cells.
LAIV infected hNEC cultures produce equivalent or greater pro-inflammatory chemokines
despite significantly reduced replication
Given the enhanced intracellular innate immune signaling in LAIV infected hNEC cultures,
chemokine expression was compared to determine if differential external cell signaling
occurs during vaccination and seasonal influenza infection of nasal epithelial cells. While
there was no significant difference in the apical secretion of IL-8 (Figure 5A), WT-infected
hNEC cultures secreted 46% more IL-8 basolaterally compared with LAIV infected cultures
(Figure 5 B). However this increase in WT induced basolateral IL-8 secretion was not
proportional to the 165 fold greater infectious virus production in WT compared with LAIV-
infected cultures (Figure 1).
In contrast to IL-8, there was significantly increased expression of IP-10 detected apically
(Figure 5 C) and basolaterally (Figure 5 D) in LAIV infected hNEC cultures compared with
WT-infected cultures at 33°C. Taken together these results suggest that infection of human
nasal epithelial cells with LAIV triggers the expression of a different chemokine profile than
seen with WT infection.
DISCUSSION
The Live Attenuated Influenza Vaccine represents an important and innovative advancement
in the prophylaxis against seasonal influenza. In contrast to the inactivated parenteral
influenza vaccine, the LAIV replicates at the site of influenza infection and is thus able to
elicit both a mucosal and systemic immune response (18). As a result, LAIV strains have
been shown to be more effective than the inactivated influenza vaccine in pediatric
populations and among hosts of all ages during years of poor homology between the
circulating strain and the vaccine strain (19–26). While in vitro and in vivo studies have
demonstrated significantly reduced LAIV infectious virus production, as compared with WT
viruses, the mechanisms underlying the LAIV’s ability to elicit a protective immune
response despite a deficient replication is unknown (27–31). In this study we compare the
replication and innate immune response during infection of primary differentiated human
nasal epithelial cells with WT and antigenically-matched cold adapted LAIV viruses at 33°C
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in order to better understand how infection with the live attenuated influenza vaccine differs
from seasonal viruses at the level of the human nasal epithelium.
Data from this study indicate that, despite significantly less infectious virus production
(Figure 1), during LAIV compared with WT hNEC infection, LAIV strains elicit an
enhanced innate immune response as evidenced by the significantly greater transcription of
RIG-I, TLR-3, IFN-beta, STAT-1, IRF-7 and MxA genes. While the reduced replication of
LAIV viruses are consistent with human clinical trials and recent in vitro infections of
human adenoid epithelial cells using the same viruses, we believe this is the first report of a
differential epithelial cell-specific innate immune response induced by WT influenza viruses
and antigenically-matched LAIV strains (30, 32). Previous reports have identified important
mutations in the LAIV backbone that are associated with the 3 novel phenotypes of LAIV
including cold adaptation, temperature sensitivity, and attenuation in animal models and
human studies, however the enhanced intracellular antiviral response following LAIV
infection likely also plays an important role in the control of virus replication and thus in the
differing clinical phenotypes elicited by LAIV and WT viruses (27–29, 31, 33). Comparison
of WT and LAIV inoculums revealed a greater hemagglutination unit titer (HAU) from the
LAIV (1:80) compared with the WT stock (1:20) despite equivalent TCID50/ml titers. This
increased HAU to TCID50/ml ratio in the LAIV inoculums, suggests the presence of greater
non-infectious virus particles in the LAIV inoculums compared with the WT inoculums, and
may contribute to the increased innate immune expression in AIV infected hNEC cultures.
The increased level of intracellular viral RNA (Figure 4) in LAIV-infected hNEC cultures,
however indicates that defective replication, rather than non-infectious virus particles offers
a more likely mechanism for the augmented innate immune response to LAIV infection.
Detection of Viral RNA by RIG-I and TLR-3 leads to the induction of antiviral gene
expression including Type I interferon as well as interferon stimulated genes (ISGs) which
are critical factors in the innate immune response to influenza infection (34, 35). Our data
demonstrate that, in addition to the up-regulation of these pattern recognition receptors
(Figure 2), transcription of IFN-beta, STAT-1, IRF-7, and MxA genes (Figure 3) is also
significantly increased in LAIV as compared with WT-infected hNECs. The increased
expression of the PRRs, RIG-I and TLR-3 are either the result of increased viral RNA
directly or more likely due to increased Type I-IFN as ISGs. Whether the increased
intracellular viral RNA is a result of defective replication due to mutations in the LAIV
backbone or a consequence of this heightened LAIV-specific epithelial cell antiviral
immune response is not clear and the subject of ongoing investigation.
The differential chemokine production that results from hNEC infection with WT and LAIV
viruses indicates that vaccination likely results in a substantially different immune cell
recruitment than wild type infection. WT-infected hNEC cultures produce significantly
greater levels of the neutrophil chemokine IL-8 whereas LAIV-infected hNEC cultures
release significantly greater levels of IP-10 (Figure 5), a chemokine that preferentially
recruits activated Th1 lymphocytes and NK cells (36). In RSV infected mice, neutralization
of IP-10 led to an increase in disease pathogenesis and impaired virus clearance highlighting
the importance of IP-10 in promoting viral clearance and generating a protective immune
response (6). The differential immune cell recruitment during infection of hNEC cultures by
LAIV and WT viruses may contribute to the decrease in LAIV replication in the human host
and explain the absent clinical phenotype during LAIV vaccination. A greater understanding
of the differences in immune cell recruitment between vaccination and wild-type infection is
needed to better understand the differential determinants of eliciting a protective immune
response versus generating a pathologic immune reaction.
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The results of this study advance our understanding of how seasonal WT influenza viruses
and antigenically matched LAIV strains differ in their ability to replicate and elicit an
immune response in the nasal epithelium. The Live Attenuated Influenza Vaccines are nasal
vaccine strains that are able to replicate in the nasal epithelium and elicit a protective
mucosal immune response without causing clinical disease. We postulate that the decreased
replication of these nasal vaccines is due to both mutations inherent in the LAIV backbone
as well as an enhanced epithelial cell specific immune response. Improved understanding of
how LAIV strains differ from WT viruses in nasal epithelial cells offers important insights
in how virus-host cell interactions can result in either a protective or pathologic response
and may also provide a way to rationally improve current LAIV strains in order to maximize
the protective immune response while limiting the expression of clinical disease.
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• We compare the immune response to and replication of influenza viruses and
live vaccines in hNECs
• Despite lower replication, the LAIV viruses elicit a more robust innate immune
response
• LAIV infection of hNECs results in a differing chemokine expression profile
immune response
• The increased innate immune response is likely due to an increase in the level of
intracellular viral RNA
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Attenuation of Infectious LAIV Virus Production during Infection of hNEC cultures at
33°C. hNEC cultures were infected with wild type (WT) and an antigenically-matched cold
adapted (CA) LAIV strain at an MOI of 10 in triplicate at 33°C. Virus titers in apical
supernatants were measured by calculating the TCID50/ml in MDCK cells at the indicated
hours post infection (HPI). The inoculum (labeled input) was back tittered in parallel. The
limit of detection is shown by the horizontal thin dotted line. Data are expressed as mean +
SEM. *** p<.001 (n=7 different donors for hNECs).
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Increased Expression of Pattern Recognition Receptors during LAIV Infection of hNEC
cultures. Total RNA from WT and LAIV infected hNECs at 24HPI was analyzed for
expression of RIG-I (A) and TLR-3 (B) by real time qRT-PCR and compared using the ΔΔ
Ct method. Data are represented as the fold change in expression from Mock infected
cultures. *p<.05 (n=7 different donors for hNECs).
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hNEC cultures Infected with LAIV Express an Augmented Antiviral Innate Immune
Response. Total RNA from hNECs collected at 24 hours post infection with WT and CA
viruses was analyzed for the expression of antiviral innate immune gene expression
including Interferon-β (A), IRF-7 (B), MxA (C), and STAT-1 (D) by real time qRT-PCR
and compared using the ΔΔ Ct method. Data are represented as the fold change in expression
from Mock infected cultures. *p<.05 (n=7 different donors for hNEC).
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LAIV infected Nasal Epithelial Cell Cultures Contain Greater Levels of Viral RNA. Total
RNA from WT and LAIV infected hNEC cultures collected at 24HPI were analyzed for the
presence of viral RNA using qRT-PCR with primers specific for the Influenza M-segment.
Levels of viral RNA were compared using the ΔΔ Ct method and represent the fold-change
in expression relative to a WT-infected sample. p<.05 (n=7 different donors for hNEC).
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WT and LAIV-Infected hNEC cultures Result in a Differential Chemokine Response.
Apical and basolateral supernatants were collected 24hours after hNEC infection with WT
and LAIV viruses and analyzed for the presence of IL-8 (A and B) and IP-10 (C and D) by
ELISA and are displayed as fold change in expression relative to Mock-infected cultures.
*p<.05 (n=7 different donors for hNEC).
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